Latest Headlines

Latest Headlines

China biotech makes a 'breakthrough' for HIV viral-entry therapy

China's TaiMed Biologics has won the FDA's breakthrough therapy designation for its HIV therapy, ibalizumab (TMB-355), making it apparently the first Chinese med to get onto the list.

GSK annual report says China bribery case spawned surge in compliance 'contacts'

It turns out the GlaxoSmithKline whistleblowers who blew the top off the China corruption scandal had hundreds of copycats later on.

China's Tianyin Pharma faces NYSE de-listing on failure to file quarterly report

China's Tianyin Pharmaceutical may be in danger of being de-listed from the New York Stock Exchange for failing to file its latest quarterly report on time.

Generic, biosimilar revenues look solid in Asia with many Indian firms eyeing innovation

Various recent reports covering the near-term and long-term outlook for the pharmaceutical industry in Asia paint a positive picture with increased revenues coming from the generics and biosimilars industries along with products as specific as human insulin from China.

American Chamber survey finds companies less sanguine on China prospects

American businesses, including members of the pharmaceutical industry, appear to be less sanguine about their prospects of doing business or expanding it in China.

Drug tender in China's Hunan province has industry up in arms

A cross-section of pharmaceutical industry players in China has objected to the steep price cuts of as much as 50% in a late January tender process in China's Hunan province.

China FDA draft GCP guidelines in line with harmonization aims

China FDA has issued draft guidelines on changes to good clinical practice guidelines that cover 34 provisions, including the use of outsourced partners in China that are generally in line with international aims of harmonization.

India plans to ramp up API output to ease China imports

India drug authorities are working on plans to increase the nation's capacity to produce its own bulk drugs in an effort to reduce its drug industry's dependence on imports, mainly from China.

India mulling plans to build bulk drug manufacturing capacity

The Indian government is expected to announce new strategies to bolster its bulk drug manufacturing capacity as part of an effort to reduce the country's dependency on Chinese API imports.

BGI eyed as capital flows into China biotech poised to grow

China sequencing giant BGI has had studies published recently having to do with things as deep as detecting novo mutations responsible for most genetic diseases to something as ordinary, yet important, as a prenatal genetic test it calls NIFTY that is nearly 100% accurate.